Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Subscribe To Our Newsletter & Stay Updated
